Qu Biologics Inc.
Qu Biologics is a pioneering biopharmaceutical company focused on developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform designed to restore normal immune function to treat and prevent cancer, chronic inflammatory diseases, metabolic diseases, and aging-related conditions. Their mission is to transform the treatment and prevention of these diseases by harnessing the body's intrinsic healing capacities through innovative immunotherapy solutions.
Industries
Nr. of Employees
small (1-50)
Qu Biologics Inc.
Vancouver, British Columbia, Canada, North America
Products
Site-specific immunomodulator platform (inactivated-bacteria-based)
A platform of organ-targeted immunotherapies composed of components from single inactivated microbial species intended to restore and train innate immune responses in specific tissues.
Site-specific immunomodulator platform (inactivated-bacteria-based)
A platform of organ-targeted immunotherapies composed of components from single inactivated microbial species intended to restore and train innate immune responses in specific tissues.
Services
Phase 2 clinical trial conduct and management
Full service clinical study operations for randomized, double-blind, placebo-controlled Phase 2 trials including protocol execution, site coordination, participant recruitment, safety monitoring and follow-up.
Clinical study recruitment and participant monitoring
Recruitment of older adult participants and management of scheduled clinical visits, blood sampling, medical record review and patient-reported outcome collection across community and care facilities.
Phase 2 clinical trial conduct and management
Full service clinical study operations for randomized, double-blind, placebo-controlled Phase 2 trials including protocol execution, site coordination, participant recruitment, safety monitoring and follow-up.
Clinical study recruitment and participant monitoring
Recruitment of older adult participants and management of scheduled clinical visits, blood sampling, medical record review and patient-reported outcome collection across community and care facilities.
Expertise Areas
- Site-specific immunomodulation
- Innate immune training and immunology
- Phase 2 clinical development and trial management
- Perioperative oncology clinical studies
Key Technologies
- Inactivated-bacteria-based immunomodulators
- Organ-targeted innate immune activation
- NK cell functional assays measuring stimulated IFN-γ
- Circulating tumor DNA (ctDNA) monitoring